Patents by Inventor Sergey Kipriyanov
Sergey Kipriyanov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9701750Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: April 20, 2015Date of Patent: July 11, 2017Assignee: Affimed GmbHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Patent number: 9226962Abstract: Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for the human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Pharmaceutical compositions containing any of the above mentioned polynucleotides, antibodies or vectors are useful for immunotherapy, preferably against acute transplant rejections.Type: GrantFiled: January 11, 2013Date of Patent: January 5, 2016Assignee: AFFIMED GMBHInventors: Fabrice Le Gall, Sergey Kipriyanov, Melvin Little, Uwe Reusch
-
Publication number: 20150218275Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: ApplicationFiled: April 20, 2015Publication date: August 6, 2015Inventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Patent number: 9035026Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: May 26, 2006Date of Patent: May 19, 2015Assignee: Affimed GMBHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Patent number: 7901677Abstract: Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen.Type: GrantFiled: April 5, 2006Date of Patent: March 8, 2011Assignee: Affimed Therapeutics AGInventors: Melvyn Little, Stefan Knackmuss, Uwe Reusch, Sergey Kipriyanov, Fabrice Le Gall, Vera Mick, Karin Hoffmann, Peter Röttgen
-
Publication number: 20090214574Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: ApplicationFiled: May 26, 2006Publication date: August 27, 2009Inventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Publication number: 20080145362Abstract: Described is a combination of at least two antibodies, characterized by the following properties: (a) it comprises at least two different multivalent antibodies, each one having at least two specificities and being characterized by features (b) and (d) or (b) and (c) as defined below, (b) an antigen-binding domain specific to a tumor antigen, (c) an antigen-binding domain specific to an antigen present on human T cells, or (d) an antigen-binding domain specific to an antigen present on CD3-epsilon negative human effector cells. Also described are polynucleotides encoding said antibodies as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Finally, compositions, preferably pharmaceutical and diagnostic compositions, are described comprising the above mentioned polynucleotides, antibodies or vectors.Type: ApplicationFiled: February 23, 2008Publication date: June 19, 2008Applicant: AFFIMED THERAPEUTICS, AGInventors: Sergey Kipriyanov, Fabrice Le Gall, Bjorn Cochlovius, Melvyn Little
-
Publication number: 20060233787Abstract: Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Pharmaceutical compositions containing any of the above mentioned polynucleotides, antibodies or vectors are useful for immunotherapy, preferably against acute transplant rejections.Type: ApplicationFiled: September 10, 2003Publication date: October 19, 2006Inventors: Fabrice Le Gall, Sergey Kipriyanov, Melvin Little, Uwe Reusch
-
Publication number: 20050176934Abstract: Described is a combination of at least two antibodies, characterized by the following properties: (a) it comprises at least two different multivalent antibodies, each one having at least two specificities and being characterized by features (b) and (d) or (b) and (c) as defined below, (b) an antigen-binding domain specific to a tumor antigen, (c) an antigen-binding domain specific to an antigen present on human T cells, or (d) an antigen-binding domain specific to an antigen present on CD3-epsilon negative human effector cells. Also described are polynucleotides encoding said antibodies as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Finally, compositions, preferably pharmaceutical and diagnostic compositions, are described comprising the above mentioned polynucleotides, antibodies or vectors.Type: ApplicationFiled: April 15, 2003Publication date: August 11, 2005Inventors: Sergey Kipriyanov, Fabrice Le Gall, Bjorn Cochlovius, Melvyn Little
-
Publication number: 20050089519Abstract: Described are multivalent multimeric antibodies comprising at least two binding sites specific for the human B cell marker CD19 and human Fc? receptor III (CD16). Also described are polynucleotides encoding said antibodies as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Finally, compositions are described comprising any of above mentioned antibodies, polynucleotides or vectors. The pharmaceutical compositions are useful for immunotherapy, preferably against B cell malignancies such as non-Hodgkin's lymphoma.Type: ApplicationFiled: November 14, 2002Publication date: April 28, 2005Inventors: Sergey Kipriyanov, Fabrice LeGall, Melvyn Little, Holger Schafer, Gerhard Moldanhauer, Bjorn Cochlovius
-
Publication number: 20050079170Abstract: The present invention relates to dimeric and multimeric antigen binding structures, expression vectors encoding said structures, and diagnostic, as well as therapeutic, uses of said structures. The antigen binding structures are preferably in the form of a Fv-antibody construct.Type: ApplicationFiled: September 13, 2002Publication date: April 14, 2005Inventors: Fabrice Le Gall, Sergey Kipriyanov, Uwe Reusch, Gerhard Moldenhauer, Melvyn Little
-
Patent number: 5911987Abstract: The present invention relates to a bonding reagent, which is characterized in that it comprises a first bonding component specific for the hemagglutinin-neuraminidase molecule of a Newcastle Disease Virus and a second bonding component specific for a costimulatorily acting molecule of an effector cell.Furthermore, this invention concerns a process for the production of the bonding reagent as well as a vaccine containing the bonding reagent and inactivated tumor cells.Type: GrantFiled: February 21, 1997Date of Patent: June 15, 1999Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Schirrmacher Volker, Khashayarsha Khazaie, Claudia Haas, Gerd Moldenhauer, Melvyn Little, Stefan Dubel, Frank Breitling, Sergey Kipriyanov, Stefanie Gotter, Hans-Jurgen Rode